NCT03966040已完成1 期
A Single-center, Open-label, Phase Ib Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) With Different Dose in Healthy Adults Aged 18-70 Years in China
Jiangsu Province Centers for Disease Control and Prevention1 个研究点 分布在 1 个国家目标入组 144 人开始时间: 2019年5月16日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 144
- 试验地点
- 1
- 主要终点
- Occurrence of solicited adverse reactions after vaccination
研究概览
简要总结
This is a single center, open-label phase1b clinical trial. The study will evaluate the safety and immunogenicity of an experimental recombinant staphylococcus aureus vaccine with different immunization schedules in healthy adults aged 18-70 years, including day 0-3-7, day 0/0-3-7, day 0/0-7 and day 0/0-7-14.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers aged 18 to 70 years (aged over 18 and under 71 years)
- •Able to comply with all clinical trial protocol requirements and willing to complete all the visit plan process during the whole clinical trial observation period.
- •Able to understand the content of informed consent and willing to sign the informed consent.
- •Able to complete the diary card independently.
- •For females only (18-49 years), a negative urine pregnancy test and willing to practice continuous effective contraception during the study.
- •Axillary temperature ≤37.0°C.
排除标准
- •• Prior receipt of Staphylococcus aureus vaccine
- •Any confirmed Staphylococcus aureus infection disease in the past 12 month.
- •History of asthma, hereditary angioneurotic edema, diabetes, malignancy or other serious disease. Participation in the clinical trial is likely to increase the disease risk and interfere with the observation of clinical trial index.
- •Prior blood donation or Blood loss over 400ml in the last 3 months;
- •Coagulation disorders (coagulation factor deficiency, coagulopathy or platelet disorder) diagnosed by doctors, or obvious bruises or blood coagulation noticed.
- •History of allergic disease likely to be exacerbated by any component of the vaccine, including allergy, urticaria, respiratory difficulty, angioneurotic edema or abdominal pain. Any autoimmune disease or immunodeficient state, parents, brother and sister with autoimmune disease or immunodeficient disease.
- •Taking immunoglobulins and/or any blood products within the last 12 months.
- •Asplenia, functional asplenia or asplenia caused by any situation or splenectomy.
- •Any acute disease or acute attack of chronic disease in last 7 days.
- •History of thyroidectomy or thyroid disease requiring treatment in the last 12 months.
- •Immunosuppressor, cytotoxic therapy, inhaled corticosteroid (excluding corticosteroids spray treatment of allergic rhinitis, acute and nonconcurrent corticosteroids treatment)
- •Participation in another research study involving receipt of an investigational product in the last 30 days.
- •Woman who is breast-feeding.
- •Prior administration of attenuated vaccine in last 28 days.
- •Prior administration of subunit vaccine, inactivated vaccine or allergic therapy in last 14 days.
- •Current anti-tuberculosis therapy or HIV infected individuals
- •Any other conditions may compromise the safety or availability of participants in the judgment of the investigator.
- •Following Immunization exclusion standard:
- •Other condition violates the inclusion criteria or meets the exclusion criteria is noticed after the first immunization.
- •Any grade 3 or more serious adverse reaction associated with vaccination since the last vaccination.
- •According to the investigator, the participant should not continue participating in the study.
研究组 & 干预措施
Immunization schedule of day 0-3-7
Experimental
Three doses of schedule given at day 0, 3 and 7.
干预措施: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7 (Biological)
Immunization schedule of day 0/0-3-7
Experimental
Four doses of schedule given at day 0/0, 3 and 7.
干预措施: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7 (Biological)
Immunization schedule of day 0/0-7
Experimental
Three doses of schedule given at day 0/0 and 7.
干预措施: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7 (Biological)
Immunization schedule of day 0/0-7-14
Experimental
Four doses of schedule given at day 0/0, 7 and 14.
干预措施: Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14 (Biological)
结局指标
主要结局
Occurrence of solicited adverse reactions after vaccination
时间窗: within 21 days after vaccination
Occurrence of solicited adverse reactions within 21 days afte vaccination with the Recombinant
次要结局
- Occurrence of unsolicited adverse reactions after vaccination(within 42 days after the vaccination)
- Specific functional antibody responses to the Staphylococcus aureus vaccine(within 42 days after vaccianation)
- Occurrence of serious adverse events after the vaccination.(within 6 months after the vaccination)
- Changes of the blood biochemistry after vaccination.(within 17 days after the vaccination)
- Antibody responses against 5 specific antigens in Staphylococcus aureus vaccine(within 42 days after vaccianation)
- Changes of the blood routine after vaccination.(within 17 days after the vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in AdultsRotator Cuff TearsMuscle Atrophy or WeaknessTendon Rupture - ShoulderSafety IssuesNCT04057833Hospital for Special Surgery, New York20
已完成
1 期
Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALSAmyotrophic Lateral SclerosisNCT06676423Corestemchemon, Inc.8
已完成
1 期
A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin CapsulesHelicobacter Pylori InfectionNCT06076681TenNor Therapeutics (Suzhou) Limited40
招募中
1 期
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic CancerPancreatic CancerNCT05911217CARsgen Therapeutics Co., Ltd.20
招募中
1 期
NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid TumorPancreatic CancerGastric CancerSolid TumorNCT06134960Peking University12